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ing 95.51 10.09. Mean rate of own health on EQ-VAS was 80.30 15.21 and mean
EQ-5D index, based on Polish TTO value set, was 0.94  0.07 (in the range from
-0.523 to 1). Students of 1st year reported lowest QoL independently of the measure
used: EQ-VAS 76.4 17.72 and EQ-index 0.92 0.07. CONCLUSIONS: Generic ques-
tionnaires used in the survey are sensitive enough for measuring quality of life in
young and relatively healthy population. Students of 1st year reported lowest qual-
ity of life with all questionnaires. The survey needs to be continued in next years.
PIH51
WHAT DO PATIENTS WITH RARE DISEASES EXPERIENCE IN THE MEDICAL
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OBJECTIVES:A growing body of evidence links effective physician-patient commu-
nication to desirable outcomes such as improved adherence to treatment and
higher satisfaction of both patient and physician. However, when it comes to rare
diseases, the patient is forced to become knowledgeable about his own disease
state and therapies. Our objective was to describe and specify the experiences of
patient-physician-interaction in rare diseases, to develop an empirically derived
typology of interaction patterns and to explore the challenges associated with each
of these patterns. METHODS: We designed a multi-case study as a series of semi
standardized interviews with patients suffering from rare diseases. Therefore we
extracted six different rare diseases: Amyotrophic lateral sclerosis, Marfan’s syn-
drome, Wilson’s disease, Epidermolysis bullosa, Duchenne muscular dystrophy
and Neurodegeneration with brain iron accumulation. A total of 120 interviews
were recorded, transcribed and analyzed thematically based on emerging codes.
RESULTS: As suggested, insufficient expertise of the health care providers proved
to be a major problem in the highly specialized treatment process of rare diseases.
Here, it is often the patient himself who becomes an expert to determine what kind
and how much service he needs. Thus, we could identify the patient-directed
interaction as a widely experienced communication pattern among patients with
rare diseases. Physician=s ability and willingness to accept the patient as an expert
emerged as a major determinant for patient satisfaction. CONCLUSIONS: People
with rare diseases often face challenges due to the low prevalence and the resulting
lack of knowledge among their providers. Our study showed the relevance of the
provider=s ability to acknowledge the active role of the patient as an informed,
involved and interactive partner in the treatment process. However, allowing the
patient to control therapy may require a change of mind-set with some long-
standing traditional roles in healthcare.
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CHILDREN: A COMPARITIVE STUDY IN THE PRIVATE HEALTH CARE SECTOR OF
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OBJECTIVES: Although the prevalence of human immunodeficiency virus (HIV)
infection among children is reported to be high, little is known about antiretroviral
(ARVs) treatment patterns. This study aims to compare medicine prescribing pat-
terns of children with HIV/AIDS to those without HIV in the private health care
sector of South Africa. METHODS: A quantitative, retrospective drug utilisation
review was performed utilising medicine claims data of a pharmacy benefit man-
agement company. Data for a four-year period (January 1, 2005 to December 31,
2008) were analysed. The study population consisted of all children 12 years,
divided into those receiving ARV medications and a control group (not receiving
ARVs). Data were analysed using the SAS® Programme (9.1). RESULTS: A total of
0.2% of all children in 2005 (N 197 323) received ARVs versus 0.4% in 2008 (N 98
939). HIV/AIDS children received 7.39 4.69 prescriptions for ARVs per year during
2005 versus 9.72  4.49 in 2008. An average 3.05  0.65 ARVs were prescribed per
prescription in 2005 versus 3.19  0.58 in 2008. HIV/AIDS children received 11.51 
7.17 prescriptions for other medication (non-ARVs) per year during 2005 and 13.46
 7.14 during 2008 compared to 3.86  3.71 (d  0.8) prescriptions per year in 2005
and 4.36 4.05 (d 1.25) in 2008 for the control group. HIV/AIDS children received
mostly sulphonamides and combinations, followed by antitussives and expecto-
rants, penicillin and combination analgesics whereas the control group received
mostly penicillin followed by antitussives and expectorants, combination analge-
sics and analgesics/antipyretics. CONCLUSIONS: There was an increase in the
number of children with HIV/AIDS over the study period. These children received
significantly more prescriptions per year than the control group. Further research
is needed to investigate the future medicine treatment cost of HIV/AIDS children in
the South African private health care sector.
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OBJECTIVES: To evaluate the alpha blockers, 5-alpha reductase inhibitors, PDE-5
inhibitor and antimuscarinic medication use in US patients diagnosed with benign
prostatic hyperplasia (BPH), lower urinary tract symptoms (LUTS) and erectile dys-
function (ED). METHODS: Employing a retrospective study design on a large US
healthcare claims database (MarketScan), male patients aged 18with a diagnosis
for BPH, LUTS and/or ED between 1/1/07 and 12/31/09 were identified. Patients with
prostatectomy were excluded. Eligible patients had 24 months of continuous phar-
maceutical and medical benefit coverage. Chi-square and Wilcoxon tests were
used to make statistical comparisons between cohorts: BPH Only (BPH), ED Only
(ED), BPHED, BPHLUTS w/o ED and BPHLUTS w/ED. RESULTS: There were
308,844 patients that met inclusion criteria, and overall 33%, 15%, 19%, and 6% had
a prescription for alpha-adrenergic antagonist, 5-alpha-reductase inhibitor, phos-
phodiesterase-inhibitor, and antimuscarinic, respectively. Overall, 53% had medi-
cation use where 6% received combination therapy, 19% switched therapy and 36%
discontinued therapy. BPH patients had higher rates of combination medication
use (8% vs. 1%, p0.0001); switching (8% vs. 7%, p0.0017) and medical visits (17 vs.
14 mean visits, p0.0001) than ED patients. However, ED had higher rates of ther-
apy discontinuation (27% vs. 15%, p0.0001) than BPH and ED. In addition, BPHED
had higher switching (15% vs. 8%, p0.0001), discontinuation (24% vs. 15%,
p0.0001) and medical visits (19 vs. 17 mean visits/yr, p0.0001) than BPH. Further-
more, BPHLUTS w/ED had higher switching (24% vs. 18%, p 0.0001), discontin-
uation (27% vs. 22%, p0.0001) and incurred more medical visits (25 vs. 23 mean
visits/yr, p0.0001) than BPHLUTS w/o ED. CONCLUSIONS: BPH and BPHLUTS
patients with ED had higher switching and discontinuation rates than patients
without ED. Thus, patients with comorbid ED may require more extensive phar-
macologic management and monitoring, resulting in more medical visits than
patients without ED.
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OBJECTIVES: The Order of Ministry of Health (N 529 from July 22, 2009) was intro-
duced system of formulary medicines in Ukraine. In 2011 the third edition of the
Ukrainian State Formulary of medicines was made. However, the State formulary
for children in Ukraine has not been adopted. METHODS: We conducted a retro-
spective analysis of a local formulary for children, according to two divisions -
Children’s neonatology and intensive care for children in an Lviv medical hospital.
We used the method of ABC-analysis, the costs and rates of provision children’s
medicines for public funds and resources for parents. RESULTS: Established that
the local formulary of children’s health-care setting contains 443 medicines with
14 ATC -groups. The major share of exchanges takes four groups: A-20%; R-16%; J
-14%; N - 12%. Determined that the cost of treatment of pulmonary surfactant
preparations is 1175 euros for one child (at June 1, 2011, 1 Euro  11,40 UAH).
Provision of surfactant for infants for the budget is only about 28%, the rest is
funded by parents. In the Formulary 17 includes antibiotics, of which only 24%
provided by the budget, the rest - at the expense of patients.Innovational antibiot-
ics financed only by 2-4% of the requirement. In children’s hospitals 2.5% took
medication extemporal production, in particular vitamin powders, solutions, pow-
ders with folic acid, solution for rehydration, and others. CONCLUSIONS: Real data
of medicines in children’s hospitals do not meet the need. Necessary to create the
State formulary for children, costs to be financed from public funds. The method of
willingness to pay to determine the list of medicines that will pay parents.
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OBJECTIVES: The use of acute hospital beds is an issue of concern both to policy-
makers and practitioners. In most countries attempts to improve efficiency and
reduce costs in this sector. One of the most widely used instruments for assessing
inappropriate hospital use is Appropriateness Evaluation Protocol (AEP), which
consists of a set of standards based on objective criteria relating to the condition of
the patient or clinical services received. The aim of this study was to measure
inappropriateness of admission and inpatient stays in four major hospitals of
Shiraz, Iran. METHODS: One of the most widely used instruments for assessing
inappropriate hospital use is Appropriateness Evaluation Protocol (AEP), which
consists of a set of standards based on objective criteria relating to the condition of
the patient or clinical services received RESULTS: Results: The results showed that
22% of the total admissions in four hospitals were rated as inappropriate. Most and
least inappropriate admissions were found in both teaching university affiliated
hospitals. Our data show that a total of 29.6% (average 6.40%) of the hospital stays
in the sample were judged to be inappropriate. The result of Least Significant
Difference (LSD) Test showed a significant association between the mean days of
inappropriate stay and turn of admission in all hospitals. In all hospitals, a signif-
icant association was observed between inappropriateness of hospital stay, costs
and length of stay.CONCLUSIONS:Considering the findings of this study and other
studies in Iran and other countries, we can conclude that factors involving in
inappropriate admission of patients in the hospitals are mostly fixed and similar
factors. To solve this problem we can use some strategy such as: Improving the
performance of the referral system, using standard criteria for an appropriate eval-
uation protocol by the medical staff, Extending of outpatient diagnosis services for
reducing of inappropriate hospitalization.
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